Identification of an Immunogenic CTL Epitope of HIFPH3 for Immunotherapy of Renal Cell Carcinoma
暂无分享,去创建一个
N. Sato | N. Masumori | H. Kitamura | T. Hasegawa | Toshiaki Tanaka | Y. Hirohashi | T. Torigoe | H. Takasu | K. Harada | T. Tsukamoto | H. Asanuma | I. Honma | Eiji Sato | N. Ito
[1] J Philip McCoy,et al. Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. , 2008, The Journal of clinical investigation.
[2] A. Harris,et al. Differential Function of the Prolyl Hydroxylases PHD1, PHD2, and PHD3 in the Regulation of Hypoxia-inducible Factor* , 2004, Journal of Biological Chemistry.
[3] D. Bowtell,et al. Siah2 Regulates Stability of Prolyl-Hydroxylases, Controls HIF1α Abundance, and Modulates Physiological Responses to Hypoxia , 2004, Cell.
[4] K. Kivirikko,et al. Characterization of the Human Prolyl 4-Hydroxylases That Modify the Hypoxia-inducible Factor* , 2003, Journal of Biological Chemistry.
[5] J. Pouysségur,et al. HIF prolyl‐hydroxylase 2 is the key oxygen sensor setting low steady‐state levels of HIF‐1α in normoxia , 2003, The EMBO journal.
[6] B. Bowen,et al. Differential regulation of HIF-1 alpha prolyl-4-hydroxylase genes by hypoxia in human cardiovascular cells. , 2003, Biochemical and biophysical research communications.
[7] Jianhe Huang,et al. Sequence Determinants in Hypoxia-inducible Factor-1α for Hydroxylation by the Prolyl Hydroxylases PHD1, PHD2, and PHD3* , 2002, The Journal of Biological Chemistry.
[8] V. Rotter,et al. Falkor, a novel cell growth regulator isolated by a functional genetic screen , 2002, Oncogene.
[9] Mircea Ivan,et al. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[10] T. Yamashita,et al. Detection and Induction of CTLs Specific for SYT-SSX-Derived Peptides in HLA-A24+ Patients with Synovial Sarcoma1 , 2002, The Journal of Immunology.
[11] K. Kamiguchi,et al. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[12] R. Figlin,et al. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. , 2001, The New England journal of medicine.
[13] N. Munshi,et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. , 2001, The New England journal of medicine.
[14] S. McKnight,et al. A Conserved Family of Prolyl-4-Hydroxylases That Modify HIF , 2001, Science.
[15] Michael I. Wilson,et al. C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation , 2001, Cell.
[16] T. Tsurumi,et al. Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8(+) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. , 2001, Blood.
[17] K. Hirata,et al. Detection of anti-livin antibody in gastrointestinal cancer patients. , 2001, Clinical chemistry.
[18] S. White,et al. HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[19] J. Yang,et al. Identification of fibroblast growth factor-5 as an overexpressed antigen in multiple human adenocarcinomas. , 2001, Cancer research.
[20] M. Kattan,et al. A postoperative prognostic nomogram for renal cell carcinoma. , 2001, The Journal of urology.
[21] Michael I. Wilson,et al. Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.
[22] M. Ivan,et al. HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing , 2001, Science.
[23] Y. Nishimura,et al. Identification of human antitumor cytotoxic T lymphocytes epitopes of recoverin, a cancer‐associated retinopathy antigen, possibly related with a better prognosis in a paraneoplastic syndrome , 2001, European journal of immunology.
[24] Eamonn R. Maher,et al. Hypoxia Inducible Factor-α Binding and Ubiquitylation by the von Hippel-Lindau Tumor Suppressor Protein* , 2000, The Journal of Biological Chemistry.
[25] J. M. Arbeit,et al. Hypoxia-inducible Factor-1α Is a Positive Factor in Solid Tumor Growth , 2000 .
[26] J. Mosnier,et al. Flow cytometric analysis of antigen expression in malignant and normal renal cells. , 2000, Anticancer research.
[27] S. Rosenberg,et al. A new era for cancer immunotherapy based on the genes that encode cancer antigens. , 1999, Immunity.
[28] B. Seliger,et al. Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? , 1998, Cancer research.
[29] P. Coulie,et al. Tumor antigens recognized by T cells. , 1997, Immunology today.
[30] A. Rickinson,et al. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. , 1997, Journal of immunology.
[31] M F del Guercio,et al. Prominent roles of secondary anchor residues in peptide binding to HLA-A24 human class I molecules. , 1995, Journal of immunology.
[32] G. Semenza,et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[33] G. Semenza,et al. Purification and Characterization of Hypoxia-inducible Factor 1 (*) , 1995, The Journal of Biological Chemistry.
[34] G. Semenza,et al. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation , 1992, Molecular and cellular biology.
[35] P. Okunieff,et al. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. , 1989, Cancer research.
[36] N. Sato,et al. Specific cytotoxicity of a long-term cultured T-cell clone on human autologous mammary cancer cells. , 1986, Cancer research.